ATE479898T1 - Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs - Google Patents

Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs

Info

Publication number
ATE479898T1
ATE479898T1 AT06784318T AT06784318T ATE479898T1 AT E479898 T1 ATE479898 T1 AT E479898T1 AT 06784318 T AT06784318 T AT 06784318T AT 06784318 T AT06784318 T AT 06784318T AT E479898 T1 ATE479898 T1 AT E479898T1
Authority
AT
Austria
Prior art keywords
methods
reagents
cancer
treatment
diagnosis
Prior art date
Application number
AT06784318T
Other languages
English (en)
Inventor
Brian Ring
Douglas Ross
Robert Seitz
Original Assignee
Applied Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genomics Inc filed Critical Applied Genomics Inc
Application granted granted Critical
Publication of ATE479898T1 publication Critical patent/ATE479898T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT06784318T 2005-02-18 2006-02-17 Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs ATE479898T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/061,067 US20060003391A1 (en) 2003-08-11 2005-02-18 Reagents and methods for use in cancer diagnosis, classification and therapy
PCT/US2006/005601 WO2006132683A2 (en) 2005-02-18 2006-02-17 Reagents and methods for use in cancer diagnosis, classification and therapy

Publications (1)

Publication Number Publication Date
ATE479898T1 true ATE479898T1 (de) 2010-09-15

Family

ID=37064199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784318T ATE479898T1 (de) 2005-02-18 2006-02-17 Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs

Country Status (8)

Country Link
US (1) US20060003391A1 (de)
EP (1) EP1856535B1 (de)
AT (1) ATE479898T1 (de)
AU (1) AU2006255766B2 (de)
CA (1) CA2598170C (de)
DE (1) DE602006016567D1 (de)
ES (1) ES2351938T3 (de)
WO (1) WO2006132683A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
WO2005098450A2 (en) * 2004-04-02 2005-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in evaluating and treating neoplastic disease conditions
EP1824564A4 (de) * 2004-10-27 2009-09-16 Uab Research Foundation Verfahren zur behandlung von gliom
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
WO2008043104A2 (en) 2006-10-06 2008-04-10 Applied Genomics Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
WO2009108932A2 (en) * 2008-02-28 2009-09-03 The Johns Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2763537T3 (es) * 2008-09-16 2020-05-29 Beckman Coulter Inc Diagrama de árbol interactivo para datos de citometría de flujo
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
JP5961809B2 (ja) * 2010-03-17 2016-08-02 国立大学法人 鹿児島大学 歯周病特異的ペプチド、並びにそれを用いた歯周病の治療および診断
WO2013007640A1 (en) * 2011-07-08 2013-01-17 Centre Leon Berard Pla2r1 as anti-tumoral compound and as biomarker for the detection of cancer
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP4269427A3 (de) * 2016-05-27 2023-11-22 Synthex, Inc. Proteinschnittstellen
WO2018094335A1 (en) * 2016-11-20 2018-05-24 The Board Of Regents Of The University Of Texas System Fine-tune modulators of neuronal excitability for neuropsychiatric disorders
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598811A (en) * 1977-01-12 1981-09-23 Hoffmann La Roche Carcinoma-associated antigens
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4666845A (en) * 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4657851A (en) * 1984-01-03 1987-04-14 Georgetown University Breast cancer diagnostic blood test
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
US4803169A (en) * 1986-02-05 1989-02-07 Cetus Corporation Assay for human breast cancer
US5843684A (en) * 1990-06-27 1998-12-01 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes
US6322989B1 (en) * 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US5593847A (en) * 1991-12-30 1997-01-14 Bayer Corporation Monitoring of NC 50/90 in blood samples of breast cancer patients
US5965362A (en) * 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US6288039B1 (en) * 1995-03-07 2001-09-11 George Washington University Pharmaceutical compositions methods and kits for treatment and diagnosis of breast cancer
JP2751886B2 (ja) * 1995-04-02 1998-05-18 ダイキン工業株式会社 乳ガン細胞の検出方法
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20040073016A1 (en) * 1996-01-11 2004-04-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US5983211A (en) * 1996-01-24 1999-11-09 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
CA2744096C (en) * 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE69704031T2 (de) * 1996-11-07 2001-06-13 Oklahoma Medical Research Foundation, Oklahoma Test zur diagnose eines erhöhten brustkrebs-risikos
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
US5840507A (en) * 1997-03-19 1998-11-24 Oncotech, Inc. Methods for cancer prognosis and diagnosis
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
WO1998042725A1 (en) * 1997-03-21 1998-10-01 Musc Foundation For Research Development Methods and compositions for diagnosis and treatment of breast cancer
AU8259798A (en) * 1997-06-20 1999-01-04 George G Klee Method for detection of breast cancer
US6063586A (en) * 1997-09-03 2000-05-16 Eye & Ear Foundation Diagnostic protocol
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
US6730477B1 (en) * 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
EP1117439A4 (de) * 1998-10-02 2002-11-20 Pro Duct Health Inc Verfahren zur identifizierung, diagnose, sowie behandlung von brustkrebs
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
US20030124543A1 (en) * 1999-01-15 2003-07-03 Stuart Susan G. Breast cancer marker
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6649342B1 (en) * 1999-03-15 2003-11-18 Eos Biotechnology, Inc. Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US6762020B1 (en) * 1999-03-15 2004-07-13 Protein Design Labs, Inc. Methods of diagnosing breast cancer
WO2001013117A2 (en) * 1999-08-13 2001-02-22 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
US6544742B1 (en) * 1999-09-03 2003-04-08 Incyte Genomics, Inc. Detection of genes regulated by EGF in breast cancer
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
US6780586B1 (en) * 1999-11-29 2004-08-24 Protein Design Labs, Inc. Methods of diagnosing breast cancer
US20020146727A1 (en) * 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
US20040142361A1 (en) * 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20030198951A1 (en) * 1999-12-02 2003-10-23 David Mack Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US20040146862A1 (en) * 2000-03-15 2004-07-29 Eos Biotechnology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20030170631A1 (en) * 2000-04-03 2003-09-11 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001075171A2 (en) * 2000-04-03 2001-10-11 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001098543A2 (en) * 2000-06-21 2001-12-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
AU2002224558A1 (en) * 2000-07-11 2002-02-05 The Regents Of The University Of California Method of diagnosing breast cancer using nipple fluid
US6631330B1 (en) * 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US20020156263A1 (en) * 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
US20020068036A1 (en) * 2000-10-13 2002-06-06 Eos Biotechnology, Inc. Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US20030157544A1 (en) * 2000-10-30 2003-08-21 Eos Biotechnology, Inc. Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20020182621A1 (en) * 2001-01-25 2002-12-05 Max Costa Methods and compositions using cap43 proteins and nucleic acids to diagnose and treat cancer and other disorders
WO2002064780A1 (en) * 2001-02-12 2002-08-22 Bionomics Limited Dna sequences for human tumour suppressor genes
US7056663B2 (en) * 2001-03-23 2006-06-06 California Pacific Medical Center Prognostic methods for breast cancer
EP1380840A4 (de) * 2001-03-27 2005-08-17 Teikoku Hormone Mfg Co Ltd Diagnoseverfahren für brustkrebs
EP1399460A4 (de) * 2001-04-27 2005-04-13 Sunnybrook & Women S College H Mit brustkrebs assoziierte gene und deren verwendung
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US20030064385A1 (en) * 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
PT1410011E (pt) * 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP2005503145A (ja) * 2001-08-16 2005-02-03 ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 非小細胞肺癌の分子特性
DE10143776A1 (de) * 2001-09-06 2003-04-03 Adnagen Ag Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US7504222B2 (en) * 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US7053663B2 (en) * 2002-03-26 2006-05-30 Intel Corporation Dynamic gate with conditional keeper for soft error rate reduction
US20050176072A1 (en) * 2002-06-21 2005-08-11 Martin Michelle D. MTA1 is a predictive and prognostic factor in human breast cancer
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
WO2004111650A1 (en) * 2003-06-06 2004-12-23 Roche Diagnostics Gmbh Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2536536A1 (en) * 2003-10-15 2005-05-06 F. Hoffmann-La Roche Ag Use of spermidine synthase (spee) as a marker for breast cancer
WO2005040812A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein ubc13 as a marker for breast cancer
ATE534037T1 (de) * 2003-10-15 2011-12-15 Hoffmann La Roche Verwendung des proteins asc als marker für brustkrebs
EP1756137A4 (de) * 2003-11-05 2007-10-31 Univ Texas Diagnostische und therapeutische verfahren und zusammensetzungen betreffend pten und brustkrebs
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
AU2005271961B8 (en) * 2004-07-09 2011-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis

Also Published As

Publication number Publication date
WO2006132683A3 (en) 2007-04-05
US20060003391A1 (en) 2006-01-05
ES2351938T3 (es) 2011-02-14
DE602006016567D1 (de) 2010-10-14
CA2598170A1 (en) 2006-12-14
EP1856535B1 (de) 2010-09-01
WO2006132683A2 (en) 2006-12-14
AU2006255766A1 (en) 2006-12-14
EP1856535A2 (de) 2007-11-21
AU2006255766B2 (en) 2013-03-28
CA2598170C (en) 2012-10-02

Similar Documents

Publication Publication Date Title
DE602006016567D1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
Goffin et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval
PH12022550578A1 (en) Method for identifying responders to smarca2/4 degraders
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
EP2657705A3 (de) Biomarker von Prostatakrebs und Verfahren zu deren Verwendung
Aktipis et al. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research
CY1119551T1 (el) Αντισωματα τα οποια δεσμευουν κυτταρο-συνδεδεμενο ca 125/0722ρ και μεθοδοι χρησης αυτων
DE602004031881D1 (de) Verfahren und materialien zur beurteilung von prostatakrebstherapien
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
TW200626900A (en) Wnt proteins and detection and treatment of cancer
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
EP2266628A3 (de) Methode zur Bestimmung der Anfälligkeit für Knochenmetastasen über die Expression von EPhA2
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
Tam et al. Neoadjuvant chemotherapy in local‐regionally advanced nasopharyngeal carcinoma: a National Cancer Database analysis
WO2005094263A3 (en) Methods of determining the prognosis and treatment of subjects with colon cancer
AU2003293556A8 (en) Methods of diagnosing and treating cancer
WO2008043104A3 (en) Reagents and methods for use in cancer diagnosis, classification and therapy
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
ATE489624T1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties